<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00808743</url>
  </required_header>
  <id_info>
    <org_study_id>RUN 2008-4198</org_study_id>
    <secondary_id>ABR nr.: NL23569.091.08</secondary_id>
    <secondary_id>CMO: 2008/148</secondary_id>
    <secondary_id>EudraCT: 2008-003696-43</secondary_id>
    <nct_id>NCT00808743</nct_id>
  </id_info>
  <brief_title>Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis</brief_title>
  <acronym>PreDuoFAP</acronym>
  <official_title>Prevention of Progression of Duodenal Adenomas to Cancer in Patients With Familial Adenomatous Polyposis (FAP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Duodenal carcinomas are the leading cause of mortality in patients with Familial Adenomatous
      Polyposis (FAP) who underwent prophylactic colorectal surgery. The purpose of this study is
      to determine wether celecoxib combined with ursodeoxycholic acid is an effective
      chemoprevention strategy to influence the progression of duodenal adenomas to carcinomas in
      patients with FAP.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in number and size of duodenal adenomas (assessed directly and by evaluation of video and photographic material from endoscopic procedures)</measure>
    <time_frame>Baseline, 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cell proliferation, in normal mucosa and adenomas (if present)</measure>
    <time_frame>Baseline, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biliary acid profile (if present)</measure>
    <time_frame>Baseline, 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Familial Adenomatous Polyposis</condition>
  <condition>Duodenal Neoplasms</condition>
  <condition>Duodenal Polyps</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive oral celecoxib twice daily and oral placebo twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral celecoxib twice daily and oral ursodeoxycholic acid twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>Celecoxib: 400mg twice daily, orally, 6 months</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ursodeoxycholic acid</intervention_name>
    <description>Ursodeoxycholic acid: orally, 6 months, dosage based on body weight:
below 50 kg: 1000mg, divided in two daily doses; 50-70 kg: 1500mg, divided in two daily doses; over 70 kg: 2000mg, divided in two daily doses</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo: orally, 6 months, dosage based on body weight:
below 50 kg: 1000mg, divided in two daily doses; 50-70 kg: 1500mg, divided in two daily doses; over 70 kg: 2000mg, divided in two daily doses</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Familial adenomatous Polyposis: APC-mutation identified or more than 100
             colorectal polyps on diagnosis

          -  Spigelman score of duodenal adenoma equal to II or III

        Exclusion Criteria:

          -  Incapability of signing informed consent

          -  Active gastric or duodenal ulcer, gastrointestinal bleeding

          -  Cardiovascular disease or risk:

               -  Congestive cardiac failure: NYHA class II to IV

               -  Proven ischemic heart disease and/or cerebrovascular disease

               -  Risk factors: hypertension, hyperlipidaemia, diabetes mellitus, family history of
                  cardiovascular events (â‰¥2 first degree family members &lt;55 years)

          -  Renal dysfunction: creatinine clearance below 50mL/min

          -  Liver dysfunction: albumin below 25 g/L or Child-Pugh-score equal to or below 10

          -  Known allergic reaction to sulfonamides, NSAIDs or ursodeoxycholic acid

          -  Use of NSAIDs or ursodeoxycholic acid for more than 1 week during the 6 months prior
             to the start of the study

          -  Use of lithium

          -  Symptomatic gallstones

          -  Inflammatory bowel disease

          -  (Possible) pregnancy or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fokko M Nagengast, MD, Ph D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center St. Radboud Nijmegen, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bjorn WH van Heumen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center St. Radboud Nijmegen, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wilbert HM Peters, Ph D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center St Radboud Nijmegen, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ellen Kampman, Ph D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center St Radboud Nijmegen, The Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center St. Radboud</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2008</study_first_submitted>
  <study_first_submitted_qc>December 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2008</study_first_posted>
  <last_update_submitted>May 15, 2013</last_update_submitted>
  <last_update_submitted_qc>May 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Familial adenomatous polyposis</keyword>
  <keyword>Adenomatous Polyposis Coli</keyword>
  <keyword>Digestive System Neoplasms</keyword>
  <keyword>Gastrointestinal Disease</keyword>
  <keyword>Intestinal disease</keyword>
  <keyword>Intestinal neoplasms</keyword>
  <keyword>Gastrointestinal neoplasms</keyword>
  <keyword>Polyps</keyword>
  <keyword>Adenoma</keyword>
  <keyword>Adenomatous Polyps</keyword>
  <keyword>Neoplastic Syndromes, Hereditary</keyword>
  <keyword>Digestive System Diseases</keyword>
  <keyword>Genetic Diseases, Inborn</keyword>
  <keyword>Chemoprevention</keyword>
  <keyword>Celecoxib</keyword>
  <keyword>Ursodeoxycholic acid</keyword>
  <keyword>Anti-Inflammatory agents, Non-Steroidal</keyword>
  <keyword>Cyclooxygenase Inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Adenomatous Polyposis Coli</mesh_term>
    <mesh_term>Duodenal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

